- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 21.01. | In J&J talc litigation, N.J. court-appointed official recommends allowing expert testimony | ||
| 21.01. | Led by Darzalex surge, J&J expects revenue to reach $100B in 2026 | ||
| 21.01. | IntraBio's Aqneursa, on a roll with EU approval, races toward another rare disease indication with phase 3 win | ||
| 21.01. | Pfizer CEO lays blame for US vaccine woes on RFK Jr.'s 'anti-science' stance: WSJ | ||
| 20.01. | GSK licenses Alteogen enzyme in bid to develop subQ Jemperli | ||
| 20.01. | Takeda's neuroscience field force hit with layoffs as key patent loss looms for Trintellix | ||
| 20.01. | Definium defines mental health applications for LSD in new awareness campaign | ||
| 20.01. | Supreme Court agrees to review 'skinny label' battle between Hikma, Amarin over generic Vascepa | ||
| 20.01. | Roche scales Genentech's North Carolina site to $2B in major obesity market play | ||
| 20.01. | Valneva withdraws chikungunya vaccine Ixchiq from US amid new FDA investigation | ||
| 20.01. | Pfizer sells its stake in GSK's ViiV for $1.9B, with Shionogi upping its ante in the HIV-focused company | ||
| 20.01. | Trump's new tariff threats around Greenland risk upending EU trade deal | ||
| 20.01. | Apiject signs lease for new generics blow-fill-seal manufacturing facility in N.C. | ||
| 16.01. | After AbbVie and Genmab's ph. 3 survival miss for Epkinly in DLBCL, what's next? | ||
| 16.01. | Single-drug Exelixis aims to be top 5 solid tumor company in the US: CEO | ||
| 16.01. | JPM26: Fujifilm CEO touts biologics capacity edge amid expansion tear | ||
| 16.01. | AbbVie's Skyrizi takes full-year TV ad spending crown yet again, with J&J's Tremfya in hot pursuit | ||
| 15.01. | Trump takes aim at insurance industry, drug prices in unveiling 'The Great Healthcare Plan' | ||
| 15.01. | FDA tells Sanofi, GSK, AstraZeneca and CSL to include warnings for febrile seizures on flu shot labels | ||
| 15.01. | FDA chides BeOne, ImmunityBio promo materials in first untitled letters of 2026 | ||
| 15.01. | JPM26: Astellas CEO resists 'rescue BD' as $6B Xtandi patent cliff nears | ||
| 15.01. | After succeeding in combo with Darzalex, J&J's Tecvayli shines as solo act | ||
| 15.01. | Hologic sets a screen to block cervical cancer with WNBA's Erica Wheeler | ||
| 15.01. | BD budgets $110M to expand Nebraska syringe production | ||
| 14.01. | JPM26: Jazz's $200M voucher sale shows drumbeat of rising prices isn't stopping |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.